{"id":"saroglitazar","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Peroxisome proliferator-activated receptor alpha","category":"target"},{"label":"PPARA","category":"gene"},{"label":"PPARG","category":"gene"},{"label":"Active","category":"status"},{"label":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","category":"indication"},{"label":"Cadila Healthcare","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Cadila Healthcare","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SAROGLITAZAR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:10.753115+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:21:31.914693+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:21:17.483198+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SAROGLITAZAR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:21:18.426305+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Peroxisome proliferator-activated receptor gamma agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:19.012492+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297530/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:21:18.902777+00:00"}},"allNames":"lipaglyn","offLabel":[],"synonyms":["saroglitazar","lipaglyn","ZYH1","saroglitazar magnesium"],"timeline":[{"date":"2013-06-26","type":"positive","source":"DrugCentral","milestone":"CDSCO (INDIA) approval (Cadila Healthcare)"}],"aiSummary":"Lipaglyn is a small molecule that acts as an agonist to the peroxisome proliferator-activated receptor alpha. It is classified as a peroxisome proliferator-activated receptor alpha agonist.","approvals":[{"date":"2013-06-26","orphan":false,"company":"CADILA HEALTHCARE","regulator":"CDSCO (INDIA)"}],"brandName":"Lipaglyn","ecosystem":[{"indication":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Peroxisome proliferator-activated receptor alpha","targets":[{"gene":"PPARA","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor alpha","protein":"Peroxisome proliferator-activated receptor alpha"},{"gene":"PPARG","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor gamma","protein":"Peroxisome proliferator-activated receptor gamma"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Saroglitazar acts as a selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), which regulates the expression of genes involved in lipid metabolism and glucose homeostasis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5047","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SAROGLITAZAR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SAROGLITAZAR","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:35:29.419622","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:21:31.915039+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"choline fenofibrate","drugSlug":"choline-fenofibrate","fdaApproval":"2008-12-15","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"clofibrate","drugSlug":"clofibrate","fdaApproval":"1967-02-08","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dodecanoic acid","drugSlug":"dodecanoic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"eicosapentaenoic acid","drugSlug":"eicosapentaenoic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"fenofibrate","drugSlug":"fenofibrate","fdaApproval":"1993-12-31","patentExpiry":"May 31, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"gemfibrozil","drugSlug":"gemfibrozil","fdaApproval":"1981-12-21","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"linolenic acid","drugSlug":"linolenic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"oleic acid","drugSlug":"oleic-acid","fdaApproval":"","relationship":"same-target"},{"drugName":"pioglitazone","drugSlug":"pioglitazone","fdaApproval":"1999-07-15","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"rosiglitazone","drugSlug":"rosiglitazone","fdaApproval":"1999-05-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"saroglitazar","indications":{"approved":[{"name":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","source":"DrugCentral","snomedId":761000119102,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"choline-fenofibrate","brandName":"choline fenofibrate","genericName":"choline fenofibrate","approvalYear":"2008","relationship":"same-target"},{"drugId":"clofibrate","brandName":"clofibrate","genericName":"clofibrate","approvalYear":"1967","relationship":"same-target"},{"drugId":"dodecanoic-acid","brandName":"dodecanoic acid","genericName":"dodecanoic acid","approvalYear":"","relationship":"same-target"},{"drugId":"eicosapentaenoic-acid","brandName":"eicosapentaenoic acid","genericName":"eicosapentaenoic acid","approvalYear":"","relationship":"same-target"},{"drugId":"fenofibrate","brandName":"fenofibrate","genericName":"fenofibrate","approvalYear":"1993","relationship":"same-target"},{"drugId":"gemfibrozil","brandName":"gemfibrozil","genericName":"gemfibrozil","approvalYear":"1981","relationship":"same-target"},{"drugId":"linolenic-acid","brandName":"linolenic acid","genericName":"linolenic acid","approvalYear":"","relationship":"same-target"},{"drugId":"oleic-acid","brandName":"oleic acid","genericName":"oleic acid","approvalYear":"","relationship":"same-target"},{"drugId":"pioglitazone","brandName":"pioglitazone","genericName":"pioglitazone","approvalYear":"1999","relationship":"same-target"},{"drugId":"rosiglitazone","brandName":"rosiglitazone","genericName":"rosiglitazone","approvalYear":"1999","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07424677","phase":"PHASE3","title":"Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy","status":"NOT_YET_RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2026-03","conditions":["Primary Biliary Cholangitis"],"enrollment":89,"completionDate":"2028-11"},{"nctId":"NCT07216235","phase":"PHASE3","title":"Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2026-02","conditions":["Primary Biliary Cholangitis"],"enrollment":386,"completionDate":"2032-11"},{"nctId":"NCT05045482","phase":"PHASE1","title":"Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease","status":"RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2021-10-21","conditions":["Hepatic Impairment","Cirrhosis","Cholestatic Liver Disease"],"enrollment":30,"completionDate":"2026-03-31"},{"nctId":"NCT06427395","phase":"PHASE3","title":"Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2024-07-16","conditions":["Primary Biliary Cholangitis"],"enrollment":150,"completionDate":"2027-07-18"},{"nctId":"NCT03617263","phase":"PHASE2","title":"Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)","status":"TERMINATED","sponsor":"Zydus Therapeutics Inc.","startDate":"2019-02-12","conditions":["Non-alcoholic Fatty Liver Disease in Women With PCOS"],"enrollment":60,"completionDate":"2024-10-28"},{"nctId":"NCT05011305","phase":"PHASE2","title":"Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2021-08-18","conditions":["Nonalcoholic Steatohepatitis","Fibrosis"],"enrollment":189,"completionDate":"2025-09-12"},{"nctId":"NCT06825559","phase":"PHASE1","title":"Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease","status":"RECRUITING","sponsor":"Zydus Therapeutics Inc.","startDate":"2025-08-05","conditions":["Cholestatic Liver Disease"],"enrollment":6,"completionDate":"2025-12-31"},{"nctId":"NCT05211284","phase":"PHASE2","title":"Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US","status":"TERMINATED","sponsor":"Zydus Therapeutics Inc.","startDate":"2022-12-08","conditions":["Nonalcoholic Fatty Liver Disease"],"enrollment":4,"completionDate":"2023-10-02"},{"nctId":"NCT05133336","phase":"PHASE2,PHASE3","title":"Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2022-04-01","conditions":["Primary Biliary Cholangitis"],"enrollment":196,"completionDate":"2025-05-07"},{"nctId":"NCT03639623","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2019-02-25","conditions":["Liver Transplant; Complications","NAFLD"],"enrollment":20,"completionDate":"2021-12-13"},{"nctId":"NCT03061721","phase":"PHASE2","title":"Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2017-04-06","conditions":["Non-Alcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis"],"enrollment":106,"completionDate":"2019-08-22"},{"nctId":"NCT03863574","phase":"PHASE2","title":"Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2019-06-12","conditions":["Non Alcoholic Steatohepatitis"],"enrollment":16,"completionDate":"2020-03-20"},{"nctId":"NCT04446507","phase":"PHASE1","title":"A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2020-07-27","conditions":["Renal Impairment"],"enrollment":32,"completionDate":"2024-05-28"},{"nctId":"NCT04469920","phase":"PHASE1","title":"Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2020-07-16","conditions":["Hepatic Impairment"],"enrollment":98,"completionDate":"2022-03-21"},{"nctId":"NCT03112681","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2017-08-18","conditions":["Primary Biliary Cirrhosis"],"enrollment":37,"completionDate":"2020-08-07"},{"nctId":"NCT05872269","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities","status":"UNKNOWN","sponsor":"Zydus Lifesciences Limited","startDate":"2023-07-20","conditions":["NAFLD","Obesity","Type 2 Diabetes","Dyslipidemias","Metabolic Syndrome"],"enrollment":1500,"completionDate":"2025-06-10"},{"nctId":"NCT03097107","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL","status":"SUSPENDED","sponsor":"Zydus Therapeutics Inc.","startDate":"2017-04-06","conditions":["Dyslipidemias"],"enrollment":124,"completionDate":"2024-01"},{"nctId":"NCT04193982","phase":"PHASE3","title":"An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)","status":"UNKNOWN","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2021-01-31","conditions":["NAFLD"],"enrollment":250,"completionDate":"2021-10-31"},{"nctId":"NCT04045769","phase":"PHASE1","title":"A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2019-08-19","conditions":["Healthy"],"enrollment":52,"completionDate":"2019-12-02"},{"nctId":"NCT04112446","phase":"PHASE1","title":"Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects","status":"COMPLETED","sponsor":"Zydus Therapeutics Inc.","startDate":"2019-09-20","conditions":["Healthy"],"enrollment":8,"completionDate":"2019-10-29"},{"nctId":"NCT02265276","phase":"PHASE3","title":"A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease","status":"UNKNOWN","sponsor":"Command Hospital, India","startDate":"2014-10","conditions":["Fatty Liver"],"enrollment":100,"completionDate":"2015-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"E0YMX3S4JD","CHEBI":"CHEBI:134708","INN_ID":"9677","UMLSCUI":"C3852920","chemblId":"CHEMBL4297530","ChEMBL_ID":"CHEMBL4297530","DRUGBANK_ID":"DB13115","PDB_CHEM_ID":"EWR","PUBCHEM_CID":"60151560","SNOMEDCT_US":"1163258006","SECONDARY_CAS_RN":"1639792-20-3","MESH_SUPPLEMENTAL_RECORD_UI":"C000588741"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Cadila Healthcare","relationship":"Original Developer"}],"publicationCount":162,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"originalDeveloper":"Cadila Healthcare","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Cadila Healthcare","companyId":"cadila-healthcare","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"CDSCO (INDIA)","status":"approved","approval_date":"2013-06-26T00:00:00.000Z","mah":"CADILA HEALTHCARE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":2},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:21:31.915039+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}